Table of Contents  

Simmons: Epigenetics and nutrition – nature versus nurture

Introduction – link of fetal malnutrition to later development of disease

It is becoming increasingly apparent that the in utero environment in which a fetus develops may have long-term effects on the subsequent health and survival of the individual.1,2The landmark cohort study of 300 000 men by Ravelli et al.3showed that exposure of expectant mothers to the Dutch famine of 1944–5 during the first half of pregnancy had resulted in significantly higher obesity rates in the resulting male children at the age of 19 years. Subsequent studies of English men demonstrated a relationship between low birthweight and the development later in life of cardiovascular disease4 and impaired glucose tolerance.58 Other studies of populations in the USA,911 Sweden,12 France,13,14 Norway15 and Finland16 have demonstrated a significant correlation between low birthweight and the later development of adult diseases. The associations between low birthweight and increased risk of coronary heart disease, stroke and type 2 diabetes mellitus (T2DM) remain strong, even after adjusting for lifestyle factors (e.g. smoking, level of physical activity, occupation, income, dietary habits or childhood socioeconomic status) and occur independent of the current level of obesity or exercise.17,18

Low birthweight and insulin secretion

It remains controversial as to whether or not the adverse effects of fetal malnutrition on glucose homeostasis are mediated through programming of the fetal endocrine pancreas.1 Growth-restricted fetuses and newborns have been reported to have either a reduced population of pancreatic betacells19 or a normal percentage of pancreatic area occupied by beta-cells.20 Both of these studies were observational; morphometric analyses were not optimal and only a small number of fetuses/newborns were examined. It is likely that a significant proportion of, but not all, growth-restricted fetuses will have reduced beta-cell numbers. A more clinically relevant consideration is the impact of fetal growth restriction on beta-cell function.

Intrauterine growth-retarded (IUGR) fetuses have been found to exhibit lower insulin and glucose levels and a higher glucose–insulin ratio in the third trimester, as measured by cordocentesis.21 Two recent studies have shown that IUGR infants display decreased pancreatic beta-cell function, but increased insulin sensitivity at birth.22,23 Low birthweight has been associated with reduced insulin response after glucose ingestion in young non-diabetic men, whereas other studies have found no impact of low birthweight on insulin secretion.17,18 However, none of these earlier studies adjusted for the corresponding insulin sensitivity, which has a profound impact upon insulin secretion. Therefore, Jensen et al.24 measured insulin secretion and insulin sensitivity in a well-matched Caucasian population of 19-year-old glucose-tolerant men with birthweights of either below the 10th percentile [small for gestational age (SGA)] or between the 50th and 75th percentiles (controls). To eliminate the major confounders such as ‘diabetes genes’, none of the participants had a family history of diabetes, hypertension or ischaemic heart disease. There was no difference between the groups with regard to current weight, body mass index (BMI), body composition or lipid profile. When controlled for insulin sensitivity, insulin secretion was reduced by 30%. Insulin sensitivity, however, was normal in the SGA patients. The investigators hypothesized that defects in insulin secretion may precede defects in insulin action and that once SGA individuals accumulate body fat, they will develop insulin resistance.24

Genetics versus environment

Several epidemiological and metabolic studies of twins and first-degree relatives of patients with T2DM have demonstrated an important genetic component of diabetes.2528 The association between low birthweight and the risk of T2DM in some studies could theoretically be explained by a genetically determined reduced fetal growth rate. In other words, the genotype responsible for T2DM may itself cause retarded fetal growth in utero. This forms the basis for the fetal insulin hypothesis, which suggests that genetically determined insulin resistance could result in low insulin-mediated fetal growth in utero as well as insulin resistance in childhood and adulthood.29 Insulin is one of the major growth factors in fetal life, and monogenic disorders that affect fetal insulin secretion or fetal insulin resistance also affect fetal growth. Mutations in the gene encoding glucokinase have been identified that result in low birthweight and maturity-onset diabetes in the young.30,31

The recently described T2DM susceptibility gene, transcription factor 7-like 2 (TCF7L2), confers a risk-allele frequency of approximately 30%.32 Studies of non-diabetic subjects show that TCF7L2 diabetesrisk genotypes alter insulin secretion.3335 A large study of 24 053 subjects combined from six studies demonstrated that TCF7L2 is the first T2DM gene to be reproducibly associated with altered birthweight. Each maternal copy of the T allele at re7903146 increased offspring birthweight by 30 g, and the investigators suggest that the most likely mechanism is reduced maternal insulin secretion resulting in maternal hyperglycaemia and increased insulin-mediated fetal growth.36

Recent genetic studies suggest that increased susceptibility to T2DM in patients who are born SGA also results from the combination of genetic factors and an unfavourable fetal environment. Polymorphisms of peroxisome proliferator-activated receptor gamma 2 (PPARγ2), a gene involved in the development and metabolic function of adipose tissue, has been shown to modulate the susceptibility of subjects who are born SGA to developing insulin resistance later in life.37,38 The polymorphism is associated with a higher risk of T2DM if only birthweight is reduced.37,38 There is obviously a close relationship between genes and environment; not only can maternal gene expression alter the fetal environment, but the maternal intrauterine environment can also affect fetal gene expression, and both influence birthweight.

Association between obesity in pregnancy and later obesity in the offspring

Obesity is one of the most pervasive and burdensome public health problems in modern times. The steady increase in overweight reproductive-age women correlates with increases in rates of childhood and infant obesity. A possible link between abnormal intrauterine environment and abnormal growth and development of offspring must be considered. Maternal obesity significantly increases fetal and neonatal adiposity in the human; thus, enhanced adipocyte development per se must play an important role in the genesis of obesity in the offspring.39

A number of epidemiological studies40,41 have shown that there is a direct relationship between birthweight and BMI in childhood and in adult life. In the US Growing Up Today study,42 a cohort study of over 14 000 adolescents, a 1-kg increment in birthweight in full-term infants was associated with an approximately 50% increase in the risk of being overweight at age 9–14 years. When adjusted for maternal BMI, the increase in risk remained significantly elevated at 30%. A study of Danish military conscripts40 showed that even after controlling for birth length and maternal factors, BMI at age 18–26 years was strongly correlated with birthweight.

What can animal models tell us?

Animal models have a normal genetic background on which environmental effects during gestation or early post-natal life can be tested for their role in inducing disease later in life. Ontogeny of beta-cell development in the rodent approximates that observed in the human.43,44 The most commonly used animal models for IUGR are calorific or protein restriction, glucocorticoid administration or induction of uteroplacental insufficiency in the pregnant rodent. In the rat, maternal dietary protein restriction (approximately 40–50% of normal intake, termed LP) throughout gestation and lactation has been reported to alter insulin secretory capacity and reduce beta-cell mass through a reduction in beta-cell proliferation rate and an increase in apoptosis.4553 Expression of pancreatic and duodenal homeobox 1 (Pdx1), a homeodomain-containing transcription factor that regulates early development of both endocrine and exocrine pancreas, and later differentiation and function of cells,54 is also reduced in islets from pups of LP mothers.55 In adulthood, rats born to LP mothers still have reductions in beta-cell mass and insulin secretion and display glucose intolerance, but usually not overt diabetes.45,46,53 In old age, LP offspring develop fasting hyperglycaemia associated with insulin resistance.5660

Total calorific restriction during the last week of pregnancy and throughout lactation also reduces beta-cell mass and impairs insulin secretion in the offspring.61,62 When maternal undernutrition is prolonged until weaning and normal nutrition is given to the offspring from weaning onwards, growth restriction and beta-cell mass reduction persists into adulthood.62

Treatment of pregnant rats with dexamethasone during the last week of gestation retards fetal growth.63 Insulin content of fetal beta-cells is reduced and is associated with a reduction in Pdx1.63

An ovine model of IUGR induced by placental insufficiency (heat-induced) results in a significant reduction in beta-cell mass in fetuses near term (0.9 of gestation) from decreased rates of beta-cell proliferation and neogenesis.64 Plasma insulin concentrations in IUGR fetuses are lower at baseline and glucose-stimulated insulin secretion is impaired. Similar deficits occur with arginine-stimulated insulin secretion. A deficiency in islet glucose metabolism also occurs in the rate of islet glucose oxidation at maximal stimulatory glucose concentrations. Thus, pancreatic islets from nutritionally deprived IUGR fetuses caused by chronic placental insufficiency have impaired insulin secretion caused by reduced glucose-stimulated glucose oxidation rates, insulin biosynthesis and insulin content. This impaired glucose-stimulated insulin secretion (GSIS) occurs despite an increased fractional rate of insulin release from a greater proportion of releasable insulin as a result of diminished insulin stores.65

To extend these experimental studies of growth restriction, we developed a model of IUGR that restricts fetal growth in the rat.6668 Growth-restricted fetal rats have critical features of a metabolic profile characteristic of growth-retarded human fetuses: decreased levels of glucose, insulin, insulin-like growth factor 1 (IGFI), amino acids and oxygen.6670 Birthweights of IUGR animals are significantly lower than those of controls until approximately 7 weeks of age, when IUGR rats catch up with controls. Between 7 and 10 weeks of age, the growth of IUGR rats accelerates and surpasses that of controls, and by 26 weeks of age, IUGR rats are obese.67 No significant differences are observed in blood glucose and plasma insulin levels at 1 week of age. Between 7 and 10 weeks of age, however, IUGR rats develop mild fasting hyperglycaemia and hyperinsulinaemia. IUGR animals are glucose intolerant and insulin resistant at an early age. First-phase insulin secretion in response to glucose is also impaired early in life in IUGR rats, before the onset of hyperglycaemia. There are no significant differences in beta-cell mass, islet size or pancreatic weight between IUGR and control animals at 1 and 7 weeks of age. In 15-week-old IUGR rats, however, the relative beta-cell mass is 50% that of controls, and by 26 weeks of age, beta-cell mass is less than one-third that of controls. This loss of beta-cell mass is accompanied by a reduction in Pdx1 expression that is greater than that in beta-cell mass.71 By 6 months of age, IUGR rats develop diabetes with a phenotype remarkably similar to that observed in humans with T2DM: progressive dysfunction in insulin secretion and insulin action.67 Thus, despite different animal models of IUGR, these studies support the hypothesis that an abnormal intrauterine milieu can induce permanent changes in beta-cell function after birth and can lead to T2DM in adulthood.

Animal model of obesity in pregnancy induces obesity in the offspring

Several investigators have used animal models of high-fat or Western-style diet-induced obesity (a diet high in fat and carbohydrate content) and have shown that maternal overnutrition induces increased adiposity and permanent changes in metabolism in the offspring.7284 Using a similar Western diet, female Sprague–Dawley rats were started on the designated diet at 4 weeks of age. The rats were mated at 12–14 weeks of age, and all resulting pups were weaned onto a control diet.85 Offspring of dams fed the Western diet had significantly increased adiposity as early as 2 weeks of age; they also showed impaired glucose tolerance compared with offspring of dams fed a control diet. Inflammation and oxidative stress were increased in preimplantation embryos, fetuses and newborns of obese dams. Oxidative stress was correlated with increased expression of pro-adipogenic and lipogenic genes in fat tissue and in preimplantation embryos. These results suggest that obesity is programmed as early as the preimplantation stage of development.

Chromatin structure, deoxyribonucleic acid methylation and gene expression

Epigenetic modifications of the genome provide a mechanism that allows the stable propagation of gene expression from one generation of cells to the next. Epigenetic states can be modified by environmental factors, which may contribute to the development of abnormal phenotypes. There are at least two distinct mechanisms through which epigenetic information can be inherited: histone modifications and deoxyribonucleic acid (DNA) methylation.86,87

In eukaryotes, the nucleosome is formed when DNA is wrapped around an octameric complex of two molecules of each of the four histones: H2A, H2B, H3 and H4. The amino termini of histones can be modified by acetylation, methylation, SUMOylation, phosphorylation, glycosylation and adenosine diphosphate (ADP) ribosylation. The most common histone modifications involve acetylation and methylation of lysine residues in the amino termini of H3 and H4. Increased acetylation induces transcription activation, whereas decreased acetylation usually induces transcription repression. Methylation of histones, on the other hand, is associated with both transcription repression and activation.86,87 Moreover, lysine residues can be mono-, di- or trimethylated in vivo, providing an additional mechanism of regulation.86,87

The second class of epigenetic regulation is DNA methylation, in which a cytosine base is modified by a DNA methyltransferase at the C5 position of cytosine, a reaction carried out by various members of a single family of enzymes.87 Approximately 70% of cytosine-phosphate-guanine (CpG) dinucleotides in human DNA are constitutively methylated, whereas most of the unmethylated CpGs are located in CpG islands. CpG islands are CG-rich sequences located near coding sequences and serve as promoters for their associated genes. Approximately half of mammalian genes have CpG islands.87 The methylation status of CpG islands within promoter sequences works as an essential regulatory element by modifying the binding affinity of transcription factors to DNA binding sites. In normal cells, most CpG islands remain unmethylated; however, in circumstances such as cancer8890 and oxidative stress they can become methylated de novo. This aberrant methylation is accompanied by local changes in histone modification and chromatin structure, such that the CpG island and its embedded promoter take on a repressed conformation that is incompatible with gene transcription. It is not known why particular CpG islands are susceptible to aberrant methylation.

Deoxyribonucleic acid methylation is commonly associated with gene silencing and contributes to X-chromosomal inactivation, genomic imprinting, as well as transcriptional regulation of tissue-specific genes during cellular differentiation.9193 It is not known why some genes are able to undergo aberrant DNA methylation; however, a study by Feltus et al.94 suggests that there is a ‘DNA sequence signature associated with aberrant methylation’. Of major significance to T2DM is their finding that Pdx1, a pancreatic homeobox transcription factor, was one of only 15 genes (of 1749 examined) with CpG islands within the promoter that were methylation susceptible (which was induced by over-expression of a DNA methyltransferase). This study demonstrates that genes essential to pancreatic development, such as Pdx1, are susceptible to epigenetic modifications, which could ultimately affect gene expression.

Histone methylation can influence DNA methylation patterns and vice versa.91 For example, methylation of lysine 9 on histone 3 (H3) promotes DNA methylation, while CpG methylation stimulates methylation of lysine 9 on H3.92 Recent evidence indicates that this dual relationship between histone methylation and DNA methylation might be accomplished by direct interactions between histone and DNA methyltransferases.91 Thus, chromatin modifications induced by adverse stimuli are self-reinforcing and can propagate.

Maternal nutritional supplementation and epigenetic modifications in the offspring

The role of environmental regulation of epigenetic phenomena in the offspring has been established by experiments performed in Agouti mice.95 Wildtype expression of the Agouti protein results in a phenotypic brown coat colour in the mouse. In this mouse model, an endogenous retrovirus-like transposon sequence is inserted close to the gene coding for the Agouti protein. An unmethylated retrotransposon promoter overrides the wild-type Agouti promoter, resulting in ectopic Agouti expression and a yellow coat colour. A methylated retrotransposon is silenced and results in a wild-type Agouti (brown) coat. Wolff et al.96 have investigated whether or not maternal diet can alter the phenotype of the Agouti mouse and found that when pregnant females are fed a diet supplemented with methyl donors, a larger proportion of the offspring have a wild-type Agouti coat colour compared with the offspring of mothers fed a standard diet. These studies indicate that the maternal methyl donor diet leads to increased methylation of the offspring’s retrotransposon. Methylation silences the offspring’s retrotransposon, allowing the wild-type Agouti promoter to be expressed, thus resulting in a mouse with a wild-type (brown) coat colour. These results suggest that maternal nutritional environmental exposure can change the stable expression of genes in the offspring through an epigenetic modification that takes place in utero.

Epigenetic regulation of gene expression in fetal growth restriction

A number of studies suggest that uteroplacental insufficiency, a common cause of IUGR, induces epigenetic modifications in offspring.97100 Epigenetic modifications affecting processes important to glucose regulation and insulin secretion, characteristics essential to the pathophysiology of T2DM, have been described in the IUGR liver, pancreatic beta-cells and muscle.97100

Chromatin remodelling in the beta-cells of intrauterine growth-retarded rats

Pancreatic and duodenal homeobox 1 is a homeodomain-containing transcription factor that plays a critical role in the early development of both the endocrine and exocrine pancreas, and in the later differentiation and function of the beta-cells. As early as 24 hours after the onset of growth restriction, Pdx1 messenger ribonucleic acid (mRNA) levels are reduced by more than 50% in IUGR fetal rats. Suppression of Pdx1 expression persists after birth and progressively declines in the IUGR animal, implicating an epigenetic mechanism.

Changes in histone acetylation are the first epigenetic modification found in beta-cells of IUGR animals. Islets isolated from IUGR fetuses show a significant decrease in H3 and H4 acetylation at the proximal promoter of Pdx1.99 These changes in H3 and H4 acetylation are associated with a loss of binding of the upstream stimulatory factor 1(USF1) to the proximal promoter of Pdx1.99 USF1 is a critical activator of Pdx1 transcription and its decreased binding markedly decreases Pdx1 transcription.101,102 After birth, histone deacetylation progresses and is followed by a marked decrease in histone 3 lysine 4 (H3K4) trimethylation and a significant increase in dimethylation of H3K9 in IUGR islets.99 H3K4 trimethylation is usually associated with active gene transcription, whereas H3K9 dimethylation is usually a repressive chromatin mark. Progression of these histone modifications parallels the progressive decrease in Pdx1 expression that manifests as a deterioration in glucose homeostasis and increased oxidative stress in the ageing IUGR animals.99 Nevertheless, at 2 weeks of age, the silencing histone modifications in the IUGR pup are responsible for suppression of Pdx1 expression since there is no appreciable methylation of CpG islands in mice at this age.99 Reversal of histone deacetylation in IUGR islets at 2 weeks of age is sufficient to nearly normalize Pdx1 mRNA levels permanently, perhaps owing to active beta-cell replication present in the neonatal rodent.99

In IUGR, Pdx1 is first silenced as a result of recruitment of corepressors, including histone deacetylase 1 (HDAC1) and mSin3A.99 These repressors catalyse histone deacetylation. Binding of these deacetylases facilitates loss of trimethylation of H3K4, further repressing Pdx1 expression.99 We found that inhibition of HDAC activity by trichostatin A (TSA) treatment normalizes H3K4me3 levels at Pdx1 in IUGR islets.99 These data suggest that the association of HDAC1 at Pdx1 in IUGR islets probably serves as a platform for the recruitment of a demethylase, which catalyses demethylation of H3K4.

The molecular mechanism responsible for DNA methylation in IUGR islets is probably dependent on the methylation status of lysine 9 on H3 (H3K9). Previous studies have shown that changes in methylation of H3K9 precede changes in DNA methylation.103,104 It has also been suggested that DNA methyltransferases may act only on chromatin that is methylated at H3K9.105 Histone methyltransferases, specifically DNA methyltransferase 3A (DNMT3A) and DNA methyltransferase 3B (DNMT3B), bind to DNA methylases, thereby initiating DNA methylation.105

These results demonstrate that IUGR induces a selfpropagating epigenetic cycle in which the mSin3A/HDAC complex is first recruited to the Pdx1 promoter, histone tails are subjected to deacetylation and Pdx1 transcription is repressed. At the neonatal stage, this epigenetic process is reversible and may define an important developmental window for therapeutic approaches. However, as dimethylated H3K9 accumulates, DNMT3A is recruited to the promoter and initiates de novo DNA methylation, which locks in the silenced state in the IUGR adult pancreas, resulting in diabetes.

How do these epigenetic events lead to diabetes?

Targeted homozygous disruption of Pdx1 in mice results in pancreatic agenesis, and homozygous mutations yield a similar phenotype in humans.106 Milder reductions in Pdx1 protein levels, as occur in the Pdx+/− mice, allow for the development of a normal mass of beta-cells,106 but result in the impairment of several events in glucose-stimulated insulin secretion.106 These results indicate that Pdx1 plays a critical role in the normal function of beta-cells106 in addition to its role in beta-cell lineage development. This may be the reason why humans with heterozygous missense mutations in PDX1 exhibit early- and late-onset forms of T2DM.106

The discovery of a critical developmental stage during which aberrant epigenetic modifications may be reversed represents a therapeutic window for the use of novel agents that could prevent common diseases with late-onset phenotypes. T2DM is one such disease, and predisposed individuals could be treated with agents that normalize the epigenetic programming of key genes, thus providing protection against development of the adult diabetic phenotype.

Genome-wide deoxyribonucleic acid methylation is disrupted in intrauterine growth-retarded islets

Epigenetic modifications are not confined to the Pdx1 locus in the IUGR rat. We mapped DNA methylation across approximately 1 000 000 loci using the Hpall tiny fragment enrichment by ligation-mediated PCR (HELP) assay.107 Comparison of IUGR with normal rats at 7 weeks of age, prior to the onset of diabetes, revealed changes in DNA methylation at a number of novel loci, not limited to canonical CpG islands or promoters. We found that IUGR in the rat causes consistent and non-random changes in cytosine methylation, affecting < 1% of HpaII sites in the genome in the islet. The majority of these changes take place not at promoters but at intergenic sequences, many of which are evolutionarily conserved. Furthermore, some of these loci are in proximity to genes manifesting concordant changes in gene expression and are enriched near genes that regulate processes that are markedly impaired in IUGR islets (e.g. vascularization, proliferation, insulin secretion and cell death).

Summary

The studies described above clearly show that environmental effects can induce epigenetic alterations, ultimately affecting expression of key genes linked to the development of T2DM including genes critical for pancreatic development and beta-cell function, peripheral glucose uptake, and insulin resistance and atherosclerosis. Recent progress in understanding epigenetic programming of gene function has led to the development of novel therapeutic agents with epigenetic targets in diseases such as cancer. Understanding the role of developmental programming of genes crucial to the development of T2DM may unveil a critical window during which epigenetic therapeutic agents could be used as a means to prevent the later development of a disease. Prior to the use of such therapeutic agents, there remains much to be learned about the programming of the epigenetic code, especially on a genome-wide scale. Much of the recent progress in understanding epigenetic phenomena is directly attributable to technologies that allow researchers to pinpoint the genomic location of proteins that package and regulate access to the DNA. The advent of DNA microarrays and inexpensive DNA sequencing has allowed many of those technologies to be applied to the whole genome. It is now possible that epigenetic profiling of CpG islands in the human genome can be used as a tool to identify genomic loci that are susceptible to DNA methylation. Aberrant methylation may then be used as a biomarker for disease. The genome-wide mapping of histone modifications by chromatin immunoprecipitation (ChIP)-chip and ChIP-seq has led to important insights regarding the mechanism of transcriptional and epigenetic memory, and how different chromatin states are propagated through the genome in yeast and in mammalian cells.108,109 Although Chip-seq experiments are currently being performed in human tissue, obstacles such as intrinsic human epigenetic variability (including age-related changes) and tissue-specific epigenetic variability must be characterized and mapped in the healthy, non-diseased state before this information can be applied to diseases such as T2DM. Eventually, genome-wide epigenetic characterization will lead to specific therapies with epigenetic targets and will also allow monitoring of genome-wide epigenetic consequences of these therapies once they are applied.

Acknowledgements

This work was supported by NIH grants: DK55704, DK078761.

Conflict of interest

The author reports no potential conflicts of interest.

References

1. 

Hales CN, Barker DJP. Type 2 diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35:595–601. http://dx.doi.org/10.1007/BF00400248

2. 

Kermack WO. Death rates in Great Britain and Sweden. Lancet 1934; 1:698–703. http://dx.doi.org/10.1016/S0140-6736(00)92530-3

3. 

Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. N Engl J Med 1976; 295:349–53. http://dx.doi.org/10.1056/NEJM197608122950701

4. 

Barker DJP. The developmental origins of adult disease. J Am Coll Nutr 2004; 23:588S–95S.

5. 

Valdez R, Athens MA, Thompson GH, et al. Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia 1994; 37:624–31. http://dx.doi.org/10.1007/BF00403383

6. 

Jaquet D, Gaboriau A, Czernichow P, et al. Insulin resistance early in adulthood in subjects born with intrauterine growth restriction. J Clin Endocrin Metab 2000; 85:1401–6. http://dx.doi.org/10.1210/jc.85.4.1401

7. 

Egeland GM, Skjaerven R, Irgrens LM. Birth characteristics of women who develop gestational diabetes: population based study. BMJ 2000; 321:546–7. http://dx.doi.org/10.1136/bmj.321.7260.546

8. 

Forsen T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176–82.

9. 

Rich-Edwards JW, Colditz GA, Stampfer MJ, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 1999; 130:278–84.

10. 

Eriksson J, Forsen T, Tuomilehto J, et al. Fetal and childhood growth and hypertension in adult life. Hypertension 2000; 36:790–4. http://dx.doi.org/10.1161/01.HYP.36.5.790

11. 

Bavdekar A, Sachdev HS, Fall CHD, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004; 350:865–75. http://dx.doi.org/10.1056/NEJMoa035698

12. 

Whincup PH, Cook DG, Adshead T, et al. Childhood size is more strongly related than size at birth to glucose and insulin levels in 10–11 year-old children. Diabetologia 1997; 40:319–26. http://dx.doi.org/10.1007/s001250050681

13. 

Martin RM, McCarthy A, Smith GD, et al. Infant nutrition and blood pressure in early adulthood: the Barry Caerphilly Growth study. Am J Clin Nutr 2003; 77: 1489–97.

14. 

Law CM, Shiell AW, Newsome CA, et al. Fetal, infant, and childhood growth and adult blood pressure: a longitudinal study from birth to 22 years of age. Circulation 2002; 105:1088–92. http://dx.doi.org/10.1161/hc0902.104677

15. 

Li C, Johnson MS, Goran MI. Effects of low birth weight on insulin resistance syndrome in Caucasian and African-American children. Diabetes Care 2001; 24:2035–42. http://dx.doi.org/10.2337/diacare.24.12.2035

16. 

Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115:290–6. http://dx.doi.org/10.1542/peds.2004-1808

17. 

Clausen JO, Borch-Johnsen K, Pedersen O. Relation between birth weight and the insulin sensitivity index in a population sample of 331 young, healthy Caucasians. Am J Epidemiol 1997; 146:23–31. http://dx.doi.org/10.1093/oxfordjournals.aje.a009188

18. 

Flanagan DE, Moore VM, Godsland IF, et al. Fetal growth and the physiological control of glucose tolerance in adults: a minimal model analysis. Am J Physiol Endocrinol Metab 2000; 278:E700–6.

19. 

Van Assche FA, De Prins F, Aerts L, et al. The endocrine pancreas in small-for dates infants. Br J Obstet Gynaecol 1977; 84:751–3. http://dx.doi.org/10.1111/j.1471-0528.1977.tb12486.x

20. 

Beringue F, Blondeau B, Castellotti MC, et al. Endocrine pancreas development in growth-retarded human fetuses. Diabetes 2005; 51:385–91. http://dx.doi.org/10.2337/diabetes.51.2.385

21. 

Econimides DL, Proudler A, Nicolaides KH. Plasma insulin in appropriate and small for gestational age fetuses. Am J Obstet Gynecol 1989; 160:1091–4.

22. 

Setia S, Sridhar MG, Bhat V, et al. Insulin sensitivity and insulin secretion at birth in intrauterine growth retarded infants. Pathology 2006; 38:236–8. http://dx.doi.org/10.1080/00313020600696256

23. 

Bazaes RA, Salazar TE, Pittaluga E. Glucose and lipid metabolism in small for gestational age infants at 48 h of age. Pediatrics 2003; 111:804–9. http://dx.doi.org/10.1542/peds.111.4.804

24. 

Jensen CB, Storgaard H, Dela F, et al. Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 2002; 51:1271–80. http://dx.doi.org/10.2337/diabetes.51.4.1271

25. 

Barnett AH, Eff C, Leslie RDG, et al. Diabetes in identical twins. Diabetologia 1981; 20:87–93. http://dx.doi.org/10.1007/BF00262007

26. 

Newman B, Selby JV, King MC, et al. Concordance for type 2 diabetes mellitus in male twins. Diabetologia 1987; 30:763–8. http://dx.doi.org/10.1007/BF00275741

27. 

Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113:909–15.

28. 

Vaag A, Henricksen JE, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for NIDDM. J Clin Invest 1995; 95:690–8. http://dx.doi.org/10.1172/JCI117715

29. 

Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999; 353:1789–92. http://dx.doi.org/10.1016/S0140-6736(98)07546-1

30. 

Froguel P, Zouali H, Vionnet N. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697–702. http://dx.doi.org/10.1056/NEJM199303113281005

31. 

Hattersley AT, Beards F, Ballantyne E, et al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 1998; 19:268–70. http://dx.doi.org/10.1038/953

32. 

Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320–3. http://dx.doi.org/10.1038/ng1732

33. 

Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55:2654–9. http://dx.doi.org/10.2337/db06-0338

34. 

Saxena R, Gianniny L, Burtt NP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55:2890–5. http://dx.doi.org/10.2337/db06-0381

35. 

Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006; 55:3630–4. http://dx.doi.org/10.2337/db06-0574

36. 

Freathy RM, Weedon MN, Bennett A, et al. Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. Am J Hum Genet 2007; 80:1150–61. http://dx.doi.org/10.1086/518517

37. 

Kubaszek A, Markkanen A, Eriksson JG, et al. The association of the K121Q polymorphism of the plasma cell glycoprotein-1 gene with type 2 diabetes and hypertension depends on size at birth. J Clin Endocrinol Metab 2004; 89:2044–7. http://dx.doi.org/10.1210/jc.2003-031350

38. 

Eriksson JG, Lindi V, Uusitupa M, et al. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 2002; 517:2321–4. http://dx.doi.org/10.2337/diabetes.51.7.2321

39. 

Catalano PM. Obesity and pregnancy – the propagation of a viscous cycle? J Clin Endocrinol Metab 2003; 88:3500–6. http://dx.doi.org/10.1210/jc.2003-031046

40. 

Sorensen HT, Sabroe S, Rothman KJ, et al. Relation between weight and length at birth and body mass index in young adulthood: cohort study. BMJ 1997; 315:1137.

41. 

Parsons TJ, Power C, Manor O. Fetal and early life growth and body mass index from birth to early adulthood in 1958 British cohort: longitudinal study. BMJ 2001; 323:1331–5. http://dx.doi.org/10.1136/bmj.323.7325.1331

42. 

Gillman MW, Rifas-Siman SL, Berkey CS, et al. Maternal gestational diabetes, and adolescent obesity. Pediatrics 2003; 111:E221–6. http://dx.doi.org/10.1542/peds.111.3.e221

43. 

Rahier J, Wallon J, Henquin J-C. Cell populations in the endocrine pancreas of human neonates and infants. Diabetologia 1981; 20:540–6. http://dx.doi.org/10.1007/BF00252762

44. 

Von Dorsche H, Reiher H, Hahn H-J. Phases in the early development of the human islet organ. Anat Anz 1988; 166:69–76.

45. 

Dahri S, Reusens B, Remacle C, et al. Nutritional influences on pancreatic development and potential links with non-insulin-dependent diabetes. Proc Nutr Soc 1995; 54:345–56. http://dx.doi.org/10.1079/PNS19950003

46. 

Dahri S, Snoeck A, Reusens-Billen B, et al. Islet function in off-spring of mothers on low-protein diet during gestation. Diabetes 1991; 40:115–20.

47. 

Snoeck A, Remacle C, Reusens B, et al. Effect of a low protein diet during pregnancy on the fetal rat endocrine pancreas. Biol Neonate 1990; 57:107–18. http://dx.doi.org/10.1159/000243170

48. 

Berney DM, Desai M, Palmer DJ, et al. The effects of maternal protein deprivation on the fetal rat pancreas: major structural changes and their recuperation. J Pathol 1997; 183:109–15. http://dx.doi.org/10.1002/(SICI)1096-9896(199709)183:1〈109::AID-PATH1091〉3.0.CO;2-B

49. 

Wilson MR, Hughes SJ. The effect of maternal protein deficiency during pregnancy and lactation on glucose tolerance and pancreatic islet function in adult rat offspring. J Endocrinol 1997; 154:177–85. http://dx.doi.org/10.1677/joe.0.1540177

50. 

Bertin E, Gangnerau MN, Bellon G, et al. Development of beta-cell mass in fetuses of rats deprived of protein and/or energy in last trimester of pregnancy. Am J Physiol Regul Integr Comp Physiol 2002; 283:R623–30.

51. 

Boujendar S, Reusens B, Merezak S, et al. Taurine supplementation to a low protein diet during foetal and early postnatal life restores a normal proliferation and apoptosis of rat pancreatic islets. Diabetologia 2002; 45:856–66. http://dx.doi.org/10.1007/s00125-002-0833-6

52. 

Petrik J, Reusens B, Arany E et al. A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat, and is associated with a reduced pancreatic expression of insulin-like growth factor-II. Endocrinology 1999; 140:4861–73. http://dx.doi.org/10.1210/en.140.10.4861

53. 

Reusens B, Remacle C. Effects of maternal nutrition and metabolism on the developing endocrine pancreas. In: Barker DJP (ed.) Fetal Origins of Cardiovascular and Lung Disease. New York, NY: Marcel Dekker Inc.; 2000. pp. 339–58.

54. 

Arantes VC, Teixeira VPA, Reis MAB, et al. Expression of PDX-1 is reduced in pancreatic islets from pups of rat dams fed a low protein diet during gestation and lactation. J Nutr 2002; 132:3030–5.

55. 

Melloul D. Transcription factors in islet development and physiology: role of PDX-1 in beta-cell function. Ann N Y Acad Sci 2004; 1014:28–37. http://dx.doi.org/10.1196/annals.1294.003

56. 

Petry CJ, Dorling MW, Pawlak DB, et al. Diabetes in old male offspring of rat dams fed a reduced protein diet. Int J Exp Diabetes Res 2001; 2:139–43. http://dx.doi.org/10.1155/EDR.2001.139

57. 

Ozanne SE, Wang CL, Coleman N, et al. Altered muscle insulin sensitivity in the male offspring of protein-malnourished rats. Am J Physiol 1996; 271:E1128–34.

58. 

Ozanne SE, Jensen CB, Tingey KJ, et al. Low birthweight is associated with specific changes in muscle insulin-signaling protein expression. Diabetologia 2005; 48:547–52. http://dx.doi.org/10.1007/s00125-005-1669-7

59. 

Ozanne SE, Olsen GS, Hansen LL, et al. Early growth restriction leads to down regulation of protein kinase C zeta and insulin resistance in skeletal muscle. J Endocrinol 2003; 177:235–41. http://dx.doi.org/10.1677/joe.0.1770235

60. 

Fernandez-Twinn DS, Wayman A, Ekizoglou S, et al. Maternal protein restriction leads to hyperinsulinemia and reduced insulin-signaling protein expression in 21-mo-old female rat offspring. Am J Physiol Regul Integr Comp Physiol 2005; 288:R368–73. http://dx.doi.org/10.1152/ajpregu.00206.2004

61. 

Garofano A, Czernichow P, Bréant B. In utero undernutrition impairs rat beta-cell development. Diabetologia 1997; 40:1231–4. http://dx.doi.org/10.1007/s001250050812

62. 

Garofano A, Czernichow P, Bréant B. Effect of ageing on beta-cell mass and function in rats malnourished during the perinatal period. Diabetologia 1999; 42:711–18. http://dx.doi.org/10.1007/s001250051219

63. 

Shen CN, Seckl JR, Slack JM, et al. Glucocorticoids suppress beta-cell development and induce hepatic metaplasia in embryonic pancreas. Biochem J 2003; 375(Pt 1):41–50. http://dx.doi.org/10.1042/BJ20030140

64. 

Limesand SW, Jensen J, Hutton JC, et al. Diminished β-cell replication contributes to reduced β-cell mass in fetal sheep with intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol 2005; 288:R1297–305. http://dx.doi.org/10.1152/ajpregu.00494.2004

65. 

Limesand SW, Rozance PJ, Zerbe GO, et al. Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology 2006; 147:1488–97. http://dx.doi.org/10.1210/en.2005-0900

66. 

Ogata ES, Bussey M, Finley S. Altered gas exchange, limited glucose, branched chain amino acids, and hypoinsulinism retard fetal growth in the rat. Metabolism 1986; 35:950–77. http://dx.doi.org/10.1016/0026-0495(86)90064-8

67. 

Simmons RA, Templeton L, Gertz S, et al. Intrauterine growth restriction leads to type II diabetes in adulthood in the rat. Diabetes 2011; 50:2279–86. http://dx.doi.org/10.2337/diabetes.50.10.2279

68. 

Boloker J, Gertz S, Simmons RA. Offspring of diabetic rats develop obesity and type II diabetes in adulthood. Diabetes 2002; 51:1499–506. http://dx.doi.org/10.2337/diabetes.51.5.1499

69. 

Simmons RA, Gounis AS, Bangalore SA, et al. Intrauterine growth restriction: Fetal glucose transport is diminished in lung but spared in brain. Pediatr Res 1991; 31:59–63. http://dx.doi.org/10.1203/00006450-199201000-00011

70. 

Unterman T, Lascon R, Gotway M, et al. Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) and hepatic mRNA are increased in the small for gestational age fetal rat. Endocrinology 1990; 127:2035–7. http://dx.doi.org/10.1210/endo-127-4-2035

71. 

Stoffers DA, Desai BM, DeLeon DD, et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 2003; 52:734–40. http://dx.doi.org/10.2337/diabetes.52.3.734

72. 

Levin BE, Govek E. Gestational obesity accentuates obesity in obesity-prone progeny. Am J Physiol Regul Integr Comp Physiol 1998; 44:R1374–9.

73. 

Howie GJ, Sloboda DM, Kamal T, et al. Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. J Physiol 2009; 587:905–15. http://dx.doi.org/10.1113/jphysiol.2008.163477

74. 

Bayol SA, Simbi BH, Stickland NC. A maternal cafeteria diet during gestation and lactation promotes adiposity and impairs skeletal muscle development and metabolism in rat offspring at weaning. J Physiol 2005; 567:951–61. http://dx.doi.org/10.1113/jphysiol.2005.088989

75. 

Buckley AJ, Keseru B, Briody J, et al. Altered body composition and metabolism in the male offspring of high fat-fed rats. Metabolism 2005; 54:500–7. http://dx.doi.org/10.1016/j.metabol.2004.11.003

76. 

Srinivasan M, Katewa SD, Palaniyappan A, et al. Maternal high-fat diet consumption results in fetal malprogramming predisposing to the onset of metabolic syndrome-like phenotype in adulthood. Am J Physiol Endocrinol Metab 2006;291:E792–9. http://dx.doi.org/10.1152/ajpendo.00078.2006

77. 

Muhlhausler BS, Adam CL, Findlay PA, et al. Increased maternal nutrition alters development of the appetite–regulating network in the brain. FASEB J 2006; 20:1257–9. http://dx.doi.org/10.1096/fj.05-5241fje

78. 

Caluwaerts S, Lambin S, van Bree R, et al. Diet-induced obesity in gravid rats engenders early hyperadiposity in the offspring. Metabolism 2007; 56:1431–8. http://dx.doi.org/10.1016/j.metabol.2007.06.007

79. 

Shankar K, Harrekk A, Liu X, et al. Maternal obesity at conception programs obesity in the offspring. Am J Physiol Regul Integr Comp Physiol 2008; 294:R528–38. http://dx.doi.org/10.1152/ajpregu.00316.2007

80. 

Samuelsson AM, Matthews PA, Argenton M, et al. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming. Hypertension 2008; 51:383–92. http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.101477

81. 

Mitra A, Albers KM, Crump EM, et al. Effect of high-fat diet during gestation, lactation or postweaning on physiological and behavioral indexes in borderline hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2008; 296:R20–8. http://dx.doi.org/10.1152/ajpregu.90553.2008

82. 

Gniuli D, Calcagno A, Caristo ME, et al. Effects of high-fat diet exposure during fetal life on type 2 diabetes development in the progeny. J Lipid Res 2008; 49:1936–45. http://dx.doi.org/10.1194/jlr.M800033-JLR200

83. 

Yan X, Zhu MJ, Xu W, et al. Up-regulation of toll-like receptor 4/nuclear factor-kB signaling is associated with enhanced adipogenesis and insulin resistance in fetal skeletal muscle of obese sheep at late gestation. Endocrinology 2010; 151:380–7. http://dx.doi.org/10.1210/en.2009-0849

84. 

Han J, Xu J, Epstein PN, et al. Long-term effect of maternal obesity on pancreatic beta cells of offspring: reduced beta cell adaptation to high glucose and high-fat diet challenges in adult female mouse offspring. Diabetologia 2005; 48:1810–18. http://dx.doi.org/10.1007/s00125-005-1854-8

85. 

Sen S, Simmons RA. Maternal antioxidant supplementation prevents obesity in the offspring of obese dams. Diabetes 2010; 59:3058–65. http://dx.doi.org/10.2337/db10-0301

86. 

Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447:407–12. http://dx.doi.org/10.1038/nature05915

87. 

Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007; 447:425–32. http://dx.doi.org/10.1038/nature05918

88. 

Yoshida H, Shigematsu H, Shivapurkar N, et al. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelialmesenchymal transition. Cancer Res 2006; 66:889–97. http://dx.doi.org/10.1158/0008-5472.CAN-05-2828

89. 

So K, Tamura G, Honda T, et al. Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia. Cancer Sci 2006; 97:1155–8. http://dx.doi.org/10.1111/j.1349-7006.2006.00302.x

90. 

Takahashi T, Shigematsu H, Shivapurkar N, et al. Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer 2006; 118:924–31. http://dx.doi.org/10.1002/ijc.21453

91. 

Cedar H, Bergman Y. Linking DNA methylations and histone modifications: patterns and paradigms. Nat Rev Genet 2009; 10:295–304. http://dx.doi.org/10.1038/nrg2540

92. 

Schubeler D, Lorincz MC, Cimbora DM, et al. Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol 2000; 20:9103–12. http://dx.doi.org/10.1128/MCB.20.24.9103-9112.2000

93. 

Gopalakrishnan S, Van Emburgh BO, Robertson KD, et al. DNA methylation in development and human disease. Mutat Res 2008; 647: 30–83. http://dx.doi.org/10.1016/j.mrfmmm.2008.08.006

94. 

Feltus FA, Lee EK, Costello JF, et al. Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 2003; 100:12253–8. http://dx.doi.org/10.1073/pnas.2037852100

95. 

Martin DI, Cropley JE, Suter CM, et al. Environmental influence on epigenetic inheritance at the Avy allele. Nutr Rev 2008; 66(Suppl. 1):S12–14.

96. 

Cooney CA, Dave AA, Wolff GL, et al. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 2002; 132:2393S–400S.

97. 

MacLennan NK, James SJ, Melnyk S, et al. Uteroplacental insufficiency alters DNA methylation, one-carbon metabolism, and histone acetylation in IUGR rats. Physiol Genomics 2004; 18:43–50. http://dx.doi.org/10.1152/physiolgenomics.00042.2004

98. 

Fu Q, McKnight RA, Yu X, et al. Uteroplacental insufficiency induces site-specific changes in histone H3 covalent modifications and affects DNA-histone H3 positioning in day 0 IUGR rat liver. Physiol Genomics 2004; 20:108–16. http://dx.doi.org/10.1152/physiolgenomics.00175.2004

99. 

Park JH, Stoffers DA, Nicholls RD, et al. Development of type 2 diabetes following intrauterine growth restriction in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 2008; 118:2316–24.

100. 

Raychaudhuri N, Raychaudhuri S, Thamotharan M, et al. Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J Biol Chem 2008; 283:13611–26. http://dx.doi.org/10.1074/jbc.M800128200

101. 

Qian J, Kaytor EN, Towle HC, et al. Upstream stimulatory factor regulates Pdx-1 gene expression in differentiated pancreatic β-cells. Biochem J 1999; 341:315–22. http://dx.doi.org/10.1042/0264-6021:3410315

102. 

Sharma S, Leonard J, Lee S, et al. Pancreatic islet expression of the homeobox factor STF-1 (Pdx-1) relies on an E-box motif that binds USF. J Biol Chem 1996; 271:2294–9. http://dx.doi.org/10.1074/jbc.271.4.2294

103. 

Li H, Rauch T, Chen ZX, et al. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 2006; 281:19489–500. http://dx.doi.org/10.1074/jbc.M513249200

104. 

Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3:89–95. http://dx.doi.org/10.1016/S1535-6108(02)00234-9

105. 

Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12:198–209. http://dx.doi.org/10.1016/S0959-437X(02)00287-3

106. 

Bernardo AS, Hay CW, Docherty K, et al. Pancreatic transcription factors and their role in the birth, life and survival of the pancreatic beta cell. Mol Cell Endocrinol 2008; 294:1–9. http://dx.doi.org/10.1016/j.mce.2008.07.006

107. 

Thompson RF, Fazzari MJ, Niu H, et al. Experimental IUGR induces alterations in DNA methylation and gene expression in pancreatic islets of rats. J Biol Chem 2010; 285:15111–18. http://dx.doi.org/10.1074/jbc.M109.095133

108. 

Lieb JD, Beck S, Bulyk ML, et al. Applying whole-genome studies of epigenetic regulation to study human disease. Cytogenet Genome Res 2006; 114: 1–15. http://dx.doi.org/10.1159/000091922

109. 

Kim TH, Barrera LO, Zheng M, et al. A high-resolution map of active promoters in the human genome. Nature 2005; 436:876–80. http://dx.doi.org/10.1038/nature03877





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA